中华医学会肺癌临床诊疗指南(2022版)

Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2022 edition)

肺癌在中国的发病率和死亡率均位于恶性肿瘤中的第1位。为进一步规范中国肺癌的防治措施、提高肺癌的诊疗水平、改善患者的预后、为各级临床医务人员提供专业的循证医学建议, 中华医学会肿瘤学分会组织呼吸内科、肿瘤内科、胸外科、放疗科、影像科和病理科专家, 以国家批准的应用指征为原则, 以国内实际可应用的药品为基础, 结合国际指南推荐意见和中国临床实践现状, 整合近年来肺癌筛查、诊断、病理、基因检测、免疫分子标志物检测和治疗手段以及随访等诊治方面的最新循证医学证据, 经过共识会议制定了中华医学会肺癌临床诊疗指南(2022版), 旨在为各级临床医师、影像、检验、康复等专业人员提供合理的推荐建议。

Lung cancer is the most common malignancy with the highest incidence and mortality in China,which poses a major public health problem.To further standardize the prevention and treatment of lung cancer,improve the prognosis of patients,and provide professional evidence-based medical recommendations to medical professionals across China,the Oncology Society of Chinese Medical Association organized experts from departments of pulmonary medicine,oncology,thoracic surgery,radiotherapy,imaging,and pathology,based on indications approved by China Food and Drug Administration,domestically available drugs,recommendations of international guidelines and current clinical practice in China,integrated the latest evidence-based medical evidence of pathology,genetic testing,immune molecular biomarker detection and treatment methods of lung cancer in recent years.After consensus meetings,the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer in China was formulated,which provided recommendations to clinicians,and imaging,laboratory,and rehabilitation professionals.